logo
logo
MXCT stock ticker logo

MaxCyte, Inc.

NASDAQ•MXCT
CEO: Mr. Maher Masoud
セクター: Healthcare
業種: Medical - Devices
上場日: 2021-07-30
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
連絡先情報
9713 Key West Avenue, Suite 400, Rockville, MD, 20850, United States
301-944-1700
www.maxcyte.com
時価総額
$87.58M
PER (TTM)
-2.0
23.7
配当利回り
--
52週高値
$2.96
52週安値
$0.64
52週レンジ
8%
順位55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$7.30M+0.00%
直近4四半期の推移

EPS

-$0.09+0.00%
直近4四半期の推移

フリーCF

-$2.92M+0.00%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Q3 Revenue Decline Total revenue $6.83M USD for Q3 2025, a 16% decrease versus Q3 2024, driven primarily by core sales contraction.
SPL Revenue Volatility Nine months SPL program revenue $2.88M USD, falling 52% due to uncertain achievement timing of clinical milestones.
SeQure Acquisition Finalized Acquired SeQure in January 2025; preliminary goodwill recorded at $3.55M USD following purchase price allocation adjustments.
Increased Operating Burn Net cash used in operating activities totaled $31.72M USD for nine months, significantly higher than the prior year period.

リスク要因

Widening Net Loss Nine months net loss reached $(35.03M) USD, increasing from $(30.46M) USD in 2024 due to lower revenue.
Cash Position Decline Cash and equivalents decreased to $12.97M USD by September 30, 2025, reflecting increased operating cash burn.
Restructuring Execution Costs Implemented 34% workforce reduction plan, incurring $3.06M USD restructuring expense during the third quarter period.
Customer Concentration Risk One customer accounted for 51% of total accounts receivable as of September 30, 2025, posing significant concentration risk.

見通し

Liquidity Runway Secured Existing cash resources expected to fund operating expenses and capital needs for at least the next 12 months.
Strategic Cost Alignment Workforce reduction plan targets 34% reduction to streamline operations and align resources with strategic priorities.
Future Revenue Expectation Expect total revenue growth as customer programs advance, driven by instrument sales and expanding SPL base.
Continued R&D Investment Expect substantial research and development expenses to support customers and develop new product offerings going forward.

同業比較

売上高 (TTM)

ATLN stock ticker logoATLN
$445.38M
+3.8%
OWLT stock ticker logoOWLT
$105.66M
+35.3%
PRE stock ticker logoPRE
$95.11M
+210.6%

粗利益率 (最新四半期)

SGHT stock ticker logoSGHT
87.3%
+2.5pp
TLSI stock ticker logoTLSI
86.7%
-2.8pp
PROF stock ticker logoPROF
66.5%
+10.6pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ARMP$428.24M-2.4158.9%374.6%
FBRX$424.90M-64.9-98.4%0.0%
CATX$320.45M-3.1-41.3%0.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-11.1%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月13日
|
EPS:-$0.10
|
売上高:$7.30M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし